But, just as antibodies are finding increasing utility in cell biology, a new Food and Drug Administration classification for those products with clinical utility may affect researchers' access to the ...

Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is linked to multiple types of ...

Jacob Lalezari of CytoDyn shares insights about CCR5-targeting therapy for cancer, including triple negative breast cancer and colorectal cancer.

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking ...

B-cell depletion is effective in MS and NMOSD, with anti-CD20 and anti-CD19 mAbs showing distinct mechanisms impacting safety and tolerability. Glycoengineering enhances ADCC activity, mitigating ...

About 8 to 10 million Americans over age 40 have an overabundance of cloned white blood cells, or lymphocytes, that hamper their immune systems. Although many who have this condition - called ...

Monoclonal antibodies (mAbs) make up one of the most important classes of advanced biotherapies. To find out about the current challenges and advances in the production of mAbs, GEN talked with Lukas ...

Climb Bio licenses CLYM116, an anti-APRIL antibody, expanding its immune-mediated disease pipeline, with preclinical data expected in 2025. Climb Bio, Inc. has announced an exclusive licensing ...

STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors Using the Mayo Clinic Biobank, we ...